Clinical Trials Logo

Impaired Insulin Secretion clinical trials

View clinical trials related to Impaired Insulin Secretion.

Filter by:
  • None
  • Page 1

NCT ID: NCT05575206 Recruiting - Type 2 Diabetes Clinical Trials

The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans

Start date: September 15, 2023
Phase:
Study type: Observational

Insulin resistance and the depletion of insulin secretion are major pathogenetic aspects of type 2 diabetes mellitus. Recently, inceptor, a receptor on the surface of beta cells was dicovered. Inceptor promotes beta cell resistance to insulin and IGF-1. In humans, the inceptor is encoded by the two genes ELAPOR1 and ELAPOR2. Whether functional mutations in these genes affect insulin secretion and glucose regulation in humans has not been investigated so far. In this study we investigate the influence of genetic variations in ELAPOR1 or ELAPOR2 on insulin secretion and glucose regulation in humans by hygerglycemic glucose clamp technique and oral glucose tolerance test respectively.

NCT ID: NCT01285232 Active, not recruiting - Clinical trials for Diabetes Mellitus Type 2

The Effect of Anakinra on Insulin Secretion

Start date: January 2011
Phase: N/A
Study type: Interventional

Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the progressive β-cell dysfunction in type 2 diabetes mellitus. Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.